A Study: Comparing the Growth Direct? Environmental Monitoring Cassette to Conventional Media - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Join Dawn McIver, President of MicroWorks, Inc, for a live webinar on June 26th  where she discusses the comparison of the Growth Direct™ Environmental Monitoring cassettes to conventional media for environmental monitoring.

A Study: Comparing the Growth Direct™ Environmental Monitoring Cassette to Conventional Media
Environmental monitoring is an integral part of the overall microbial testing performed as part of pharmaceutical manufacturing. The traditional method includes the use of standard contact plates and media.  Samples are captured, the contact plate incubated and the number of colony forming units (CFUs) reported. While a time tested technique, the compendial test is time consuming and open to errors in counting or recording of results. The Growth Direct™ System helps to automate the incubation, enumeration and reporting using a proprietary cassette with traditional media. Join Dawn McIver, President of MicroWorks, Inc, as she discusses the comparison of the Growth Direct™ Environmental Monitoring cassettes to conventional media for environmental monitoring.
The live event is on June 26th at 11am Eastern Time and will be available on demand. Register at www.rapidmicrobio.com

Contact details: Mark Severns
Email: info@rapidmicrobio.com
Web address: http://www.rapidmicrobio.com/webinar-june-26-2014

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here